Panelists discuss how to operationalize bispecific antibody (BsAb) therapy in community practices, summarizing the toxicities associated with CD3×CD20 BsAbs and presenting consensus recommendations for their management.
Video content above is prompted by the following:
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy